New findings highlight Telomir-1's impact on CASP8 and GSTP1, two critical genes that regulate cell death and glutathione-based detoxification pathways often disrupted in cancer. MIAMI, FLORIDA / ACCESS Newswire / October 23, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical biotechnology company developing therapies that target the epigenetic roots of cancer, aging, and age-related disease, today reported new preclinical data from an in vivo study in mice beari ...

ROCKVILLE, MD / ACCESS Newswire / October 21, 2025 / Radiation therapy has always been the heavyweight of cancer treatment. It works, but it's a brute. ...

公司业务进展 - 公司与GenFleet Therapeutics合作开发GFH375 (VS-7375) 用于治疗晚期KRAS G12D突变胰腺导管腺癌 旨在为治疗选择有限的患者提供新方案 可能改变治疗格局 [1][4] - GFH375针对的是具有挑战性的癌症突变 其潜在成功可能提升公司的市场地位和财务前景 [1][4] 市场评级与股价表现 - RBC Capital维持对公司"跑赢大盘"评级 尽管公司市盈率为负3.38倍 当前股价为8.32美元 [2] - RBC Capital给出的目标价为13美元 暗示股价有62.3%的上涨潜力 反映了对其战略举措和潜在突破的信心 [2][5] 财务状况分析 - 公司企业价值与经营现金流比率为负3.62倍 显示其产生正现金流存在困难 [3] - 公司流动比率为3.46 表明其偿付短期负债能力强 [3] - 公司负债权益比为2.09 显示其负债多于权益 [4]

On Saturday, Genmab A/S (NASDAQ:GMAB) revealed updated data from cohort B2 of the Phase 1/2 RAINFOL-01 trial evaluating rinatabart sesutecan (Rina-S) in heavily pretreated patients with advanced endometrial cancer. The study showed that at a median study follow-up of one year, treatment with Rina-S 100 mg/m² every 3 weeks (Q3W) resulted in a 50.0% confirmed objective response rate (ORR), including two complete responses (CR).ORR is the percentage of patients in a study whose cancer shows a significant, meas ...

OCALA, Fla., Oct. 20, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced it will participate at the 2025 Maxim Growth Summit, taking place October 22-23, 2025 in New York, NY. This prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries. As part of the conference, members of management will be available to participate in in-person one-on-one meetin ...

业绩总结 - Ivonescimab与化疗联合使用在中位无进展生存期(mPFS)上表现出显著改善，mPFS为11.14个月，相较于Tislelizumab的6.90个月提高了4.24个月[21] - Ivonescimab的风险比(HR)为0.60，95%置信区间为(0.46, 0.78)，p值小于0.0001，显示出统计学上的显著性[21] - Ivonescimab的客观缓解率(ORR)为75.6%，而Tislelizumab为66.5%[38] 用户数据 - 试验共招募532名患者，分为Ivonescimab组和Tislelizumab组，各266名[12] - Ivonescimab组的中位随访时间为10.28个月[21] - Ivonescimab + FOLFOXIRI组的中位随访时间为9.0个月（范围：6.3-11.3）[97] 新产品和新技术研发 - Ivonescimab加化疗的中位持续反应时间(mDoR)为11.20个月，而Tislelizumab加化疗为8.38个月，p值为0.0219[41] - Ivonescimab与FOLFOXIRI联合治疗的客观反应率（ORR）为81.8%（95% CI: 59.7-94.8）[97] - Ivonescimab与FOLFOXIRI联合治疗的疾病控制率（DCR）为100%（95% CI: 84.6-100）[97] 安全性和不良事件 - Ivonescimab组中，99.2%的患者经历了治疗相关不良事件(TRAE)，其中63.9%为3级及以上TRAE[47] - Ivonescimab组中，32.3%的患者出现严重TRAE，导致9名患者停药，8名患者死亡[47] - Ivonescimab组中，27.4%的患者经历免疫相关不良事件(irAE)，其中9.0%为3级及以上[55] 市场扩张和监管 - Ivonescimab目前仅获得中国国家药品监督管理局(NMPA)的批准，尚未获得其他监管机构的批准[43] - HARMONi-6研究在中国进行，完全由Akeso赞助和管理[50] 其他新策略和有价值的信息 - 该研究为多中心、随机、双盲、平行对照的III期临床试验，主要评估无进展生存期[11] - 该研究的截止日期为2024年2月29日[97] - 该研究排除了已知的MSI高或dMMR肿瘤患者[93]

临床研究结果 - 皮下注射amivantamab单药治疗在HPV阴性、对PD-1/PD-L1抑制剂和铂类化疗耐药的复发性或转移性头颈鳞状细胞癌患者中，显示出45%的总缓解率[1][3] - 治疗响应迅速，中位首次响应时间为6.4周，且响应持久，中位缓解持续时间为7.2个月[3] - 在8.3个月随访后，82%的患者观察到靶病灶肿瘤缩小[1][3] - 中位无进展生存期为6.8个月，中位总生存期尚未达到[3] 药物优势与特点 - 皮下注射剂型可在5分钟内完成手动注射，相较于静脉注射的RYBREVANT，为患者提供了更大的便利性[1] - RYBREVANT是全球首个获批用于肺癌的双特异性抗体，可抑制EGFR和MET，并激活免疫系统攻击癌细胞[2] - EGFR和MET在80%至90%的头颈鳞状细胞癌肿瘤中过度表达，是潜在的治疗靶点[2] 安全性与耐受性 - 在86名安全性可评估患者中，安全性特征与之前的皮下注射amivantamab单药研究一致，未观察到新的安全信号[4] - 最常见的治疗相关不良事件为疲劳（31%）、低白蛋白血症（31%）和口腔炎（23%）[4] - 仅7%的患者出现给药相关反应，均为轻度至中度，无严重事件；因治疗相关不良事件导致停药的患者比例为2%[4] 疾病背景与市场机会 - 头颈鳞状细胞癌是最常见的头颈癌类型，占所有头颈癌病例的90%以上，约占全球所有癌症的4.5%[8] - 约75%的头颈鳞状细胞癌病例为HPV阴性，通常预后较差，对治疗的反应也较差[8] - 该患者群体在PD-1/PD-L1抑制剂和铂类化疗疾病进展后选择有限，现有疗法的缓解率通常仅为10%至24%，中位生存期为6至9个月[2] 后续开发计划 - 基于该结果，公司启动了3期OrigAMI-5研究，评估一线皮下注射amivantamab联合pembrolizumab和卡铂的疗效[5] - 这些发现为RYBREVANT为基础的治疗在多种实体瘤（包括非小细胞肺癌、结直肠癌和头颈鳞状细胞癌）中的作用提供了更多证据[6] - 皮下注射amivantamab是一种研究性双特异性抗体amivantamab与重组人透明质酸酶PH20的固定剂量组合，正在多种肿瘤类型中进行研究[9]

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced updated follow-up results from the single-arm Phase 2 PHAROS trial evaluating BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for the treatment of adults with metastatic non-small cell lung cancer (mNSCLC) with a BRAF V600E mutation. In treatment-naïve patients, the median overall survival (OS) was 47.6 months (95% confidence interval [CI], 31.3, not estimable) after a median follow-up of 52.3 months. In previously treated pati. ...

New safety and pharmacokinetic data from Phase 3 C-POST trial provide insights on an every 6-week dosing regimen of adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell carcinomaTARRYTOWN, N.Y., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data from its advancing oncology pipeline will be shared in seven abstracts at the European Society for Medical Oncology (ESMO) 2025 Meeting, taking place from October 17-21 in Berlin, Germ ...

CLR 225 (225Ac-phospholipid ether) Demonstrates Meaningful Inhibition of Tumor Growth and Potential Survival Benefit In Three Pancreatic Cancer Xenograft ModelsFLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief operating officer of Cellectar, presented positive preclinical data in a poster at t ...